Valproic acid treatment of glioblastoma multiforme in a child [4]

Pediatric Blood and Cancer

Volumn 43, Issue 2, 2004, Pages 181-

  Witt, Olaf ^a   Schweigerer, Lothar ^a   Hernáiz Driever, Pablo ^b   Wolff, Johannes ^c   Pekrun, Amulf ^d  

^a UNIVERSITY OF GÖTTINGEN   (Germany)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^c St Hedwig Childrens Hospital   (Germany)

^d Children's Hospital   (Germany)

Author keywords

Child; Glioblastoma; HDAC; Valproic acid

Indexed keywords

CISPLATIN; ETOPOSIDE; HISTONE DEACETYLASE; HISTONE DEACETYLASE INHIBITOR; IFOSFAMIDE; TOPOTECAN; VALPROIC ACID; VINCRISTINE;

ANTINEOPLASTIC ACTIVITY; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CASE REPORT; DROWSINESS; EPILEPSY; GLIOBLASTOMA; HUMAN; LETTER; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; PSYCHOMOTOR DISORDER; SCHOOL CHILD; SEIZURE; SIDE EFFECT; TUMOR RECURRENCE; TUMOR VOLUME;

CHILD; ENZYME INHIBITORS; GLIOBLASTOMA; HISTONE DEACETYLASES; HUMANS; MALE; VALPROIC ACID;

EID: 3042831930     PISSN: 15455009     EISSN: None     Source Type: Journal    
DOI: 10.1002/pbc.20083     Document Type: Letter

References (3)

1. Marks PA, Rifkind RA, Richon VM, et al. Histone deacetylases and cancer: Causes and therapies. Nat Rev Cancer 2001;1:194-202.
2. Knuepfer M, Hernáiz Driever P, Poppenborg H, et al. Valproic acid inhibits growth and changes CD 44 and CD 56 expression of malignant glioma cells. Anticancer Res 1998;18:3585-3589.
3. Göttlicher M, Minucci S, Zhu P, et al. Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells. EMBO J 2001;20:6969-6978.